Is AVEO Pharmaceuticals, Inc. (AVEO) Stock a Good Buy in Biotechnology

Tuesday, November 5, 2019 9:48 AM | InvestorsObserver Analysts

The 42 rating InvestorsObserver gives to AVEO Pharmaceuticals, Inc. (AVEO) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 48 percent of stocks in the Biotechnology industry, AVEO’s 42 overall rating means the stock scores better than 42 percent of all stocks.

Click Here to get the full Stock Score Report on AVEO Pharmaceuticals, Inc. (AVEO) Stock.

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With AVEO Pharmaceuticals, Inc. Stock Today?

AVEO Pharmaceuticals, Inc. (AVEO) stock is flat -0.25% while the S&P 500 is higher by 0.01% as of 9:46 AM on Tuesday, Nov 5. AVEO is flat $0.00 from the previous closing price of $0.57 on volume of 317,977 shares. Over the past year the S&P 500 is up 12.43% while AVEO is lower by -77.56%. AVEO lost -$0.04 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for AVEO Pharmaceuticals, Inc. click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

40% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 57% with annual

InvestorsObserver Premium

$ 20.75 $ 12.45 /month
$249 $149.40 billed annually

You May Also Like

Related Articles

Does NextCure Inc (NXTC) Stock Have Analysts Confidence?

Wall Street's Thoughts on Rewalk Robotics Ltd (RWLK) Stock

Do Analysts Expect Evofem Biosciences Inc (EVFM) Stock to Rise Next Year?

Has OncoCyte Corp (OCX) Stock's Performance Changed Wall Street's View?

Do Analysts Agree on OptiNose Inc (OPTN) Stock's Target Price?

Related Companies